Argo Blockchain
ARBK
Strategy
MSTR
BTCS Inc
BTCS
Canaan
CAN
Bit Origin
BTOG
US Stock MarketDetailed Quotes
COSM Cosmos Health
- 0.6193
- -0.0207-3.23%
Close Feb 14 16:00 ET
- 0.6199
- +0.0006+0.10%
Post 19:46 ET
14.40MMarket Cap-0.25P/E (TTM)
0.6500High0.6112Low414.30KVolume0.6310Open0.6400Pre Close259.29KTurnover2.60%Turnover RatioLossP/E (Static)23.26MShares1.580052wk High0.41P/B9.88MFloat Cap0.467752wk Low--Dividend TTM15.95MShs Float194.2500Historical High--Div YieldTTM6.06%Amplitude0.4677Historical Low0.6250Avg Price1Lot Size
Trending Stocks
U.S. Crypto Concept Stocks U.S. Crypto Concept Stocks
Companies involved in the creation, trade, and services of digital forms of money.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S. Crypto Concept Stocks, ranked from highest to lowest based on real-time market data. Companies involved in the creation, trade, and services of digital forms of money.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S. Crypto Concept Stocks, ranked from highest to lowest based on real-time market data.
Cosmos Health Stock Forum
another big 13 g filed 9.99%
something big coming
CHICAGO, IL / ACCESS Newswire / January 21, 2025 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that its CEO, Greg Siokas, has increased his stake in the Company by acquiring a total of 647,80...
with so many positive news and outcomes, the shorties are still lowering the price so that they can load more. I hope the holders won’t sell it at bargain. This company have growth potential.
NFA
The development of CCX0722 marks a strategic entry into the burgeoning weight management market, with several noteworthy technical and market implications. The pursuit of Class III medical device classification is particularly significant, as this category typically requires the highest level of regulatory scrutiny and clinical evidence. This classification, while demanding more rigorous testing and validation, could provide substantial market ad...
Cosmos Health's Novel Weight Loss Device Enters Clinical Phase, Eyes Massive $142B Market Opportunity
Cosmos Health Enters Final Development Phase of CCX0722 Weight Management Solution; Expected Product Launch in Q1 or Q2 2026, Gaining Access to Over $142 Billion Market
Tuesday, 11th February at 10:15 am
• Finalizing scale-up production phase
• Engaging with Contract Research Organizations to complete the technical dossier
• Clinical trials expected to complete in late 2025 or early 2026
• Potential classification as a Class III medical device
• Product launch e...
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, ...
AI Breakthrough: Cosmos Health's Dual Cancer Patents Could Revolutionize $25B Treatment Market
The dual-market strategy targeting both gliomas and hematologic malignancies positions Cosmos Health in two distinct but complementary oncology segments. The glioma market, while smaller at $5.1B by 2032, represents a less crowded space with significant unmet needs. The 5.20% CAGR reflects steady growth driven by increasing diagnosis rates and an aging...
The patent filings by Cosmos Health represent a strategically significant move in the oncology space, particularly notable for their AI-driven approach to drug repurposing. Drug repurposing typically offers several key advantages over traditional drug development: reduced development costs, shorter time to market and lower failure rates due to established safety profiles.
The company's focus on both gliomas and hematologic malignancies is partic...
No comment yet